Skip to main content

Advertisement

Table 1 Hospital Readmission Rates and Average Readmission Costs for Medication-Based Patient Cohorts: 1999–2010. The readmission percentage is found by dividing the number readmitted to the hospital by the total number of patients who experienced an initial diabetes-related hospitalization. Readmission cost is expressed in 2010 U.S. dollars

From: Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes

Patient Cohort Total number (SE) Number not readmitted (SE) Number readmitted (SE) Readmission percentage Mean readmission cost (SE)
All Patients 13,537,803 (519,634) 10,959,266 (451,218) 2,578,538 (198,384) 19.1 $8,814 ($580)
All SU Patients a 7,871,912 (368,351) 6,204,869 (326,273) 1,667,043 (153,735) 21.2 $9,204 ($769)
SU (SU monotherapy) b 3,217,089 (235,951) 2,470,510 (194,884) 746,579 (106,554) 23.2 $11,148 ($1,558)
SU+ (other AHA) 4,654,823 (274,495) 3,734,359 (247,494) 920,464 (113,487) 19.8 $7,624 ($412)
All Other Oral AHA Patients a 5,665,891 (291,467) 4,754,397 (256,821) 911,495 (108,690) 16.1 $8,098 ($737)
noSU (monotherapy with non-SU AHA) b 5,488,379 (288,154) 4,606,396 (254,357) 881,984 (107,289) 16.1 $7,673 ($763)
noSU+ (> 1 non-SU AHA) 177,512 (na) 148,001 (na) 29,511 (na) 16.6 $20,772 (na)
  1. SE standard error
  2. na not available due to too low raw cell count
  3. SU sulfonylurea
  4. AHA antihyperglycemic agent
  5. a In a comparison between all SU (SU and SU+) patients and all other oral AHA patients, the relevant p-value for readmission rates was 0.017
  6. b In a comparison between SU patients and noSU monotherapy patients, the relevant p-value for readmission rates was 0.003